• Home
  • Study Details
By physician referral or invitation only

SARS-CoV-2 Immune Responses after COVID-19 Therapy and Subsequent Vaccine"

This study is for people who had COVID-19 and participated in ACTIV-2/A5401 and received either experimental treatment, a standard of care COVID-19 treatment, or placebo. This study is also for people who have not previously had a COVID-19 infection. The study is designed to evaluate how the immune system responds to mRNA-COVID-19 vaccines in these participants. The safety of mRNA COVID-19 vaccines in persons with prior COVID-19 who did and did not receive prior experimental treatment for COVID-19 will be explored.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team


Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

David Wohl
Medicine-Infectious Diseases

Study Type

Clinical or Medical

Study Topics


IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.